Genentech Defends Herceptin Dosing Patents Before PTAB

Law360, Alexandria, Va. (May 8, 2018, 9:52 PM EDT) -- Genentech Inc. defended two dosage patents for blockbuster breast cancer drug Herceptin against assertions of obviousness by Hospira Inc. by telling a Patent Trial and Appeal Board panel the Pfizer Inc. unit had failed to show a skilled practitioner in 1999 would have expected the drug to remain effective after three weeks.

Hospira lawyer Amanda Hollis of Kirkland & Ellis LLP told the panel the only novel invention now claimed by Genentech is the once-in-three-weeks injection timetable. But that isn’t even the primary invention claimed by...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.